News

Merck (MRK) recently announced a dividend of $0.81 per share for Q4 2025 and gained Health Canada approval for KEYTRUDA® in treating cervical cancer. These developments align with Merck’s ongoing ...
Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently ...
Merck (MRK) announced on Monday that the Canadian regulator, Health Canada, has granted approval for its cancer drug Keytruda in combination with chemoradiotherapy (CRT) for the treatment of ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
ZoomRx surveyed 57 neurologists in the U.S. this month, revealing that no single drug brand holds more than 5% of top-of-mind ...
Merck & Co. faces headwinds despite being labeled an undervalued stock. Morgan Stanley recently lowered its price target to ...
Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...
Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...
Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...
Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...
AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...